Recombinant adenovirus vector tumor vaccine, preparation method therefor, and use thereof

By using a recombinant adenovirus vector to encode a mutant KRAS protein antigen peptide and fusion protein, and combining it with the mucosal immune pathway, the shortcomings of existing tumor vaccines in terms of specificity and tolerability are overcome, achieving a highly efficient immune response and preventive effect against Kras-driven tumors.

WO2026119155A1 Publication Date: 2026-06-11BRITIE BIOTECH CO LTD
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
BRITIE BIOTECH CO LTD
Filing Date
2025-12-02
Publication Date
2026-06-11

AI Technical Summary

⚠Technical Problem

Existing cancer vaccines suffer from insufficient specificity and tolerability issues when targeting tumor-associated antigens or tumor-specific antigens, resulting in weak immune responses and difficulty in effectively preventing tumor growth and recurrence.

⚗Method used

The recombinant adenovirus vector encodes a specific mutant antigenic peptide epitope of the KRAS protein and combines it with fusion proteins that promote and enhance the presentation and enhancement of cellular immune antigens, such as LC3B, IFN-γ, IL12, GM-CSF, IL21, CCL3, and CCL5, to enhance the immune response through mucosal immune pathways such as nebulized inhalation.

🎯Benefits of technology

It improved the killing effect on Kras-driven tumors such as lung cancer, pancreatic cancer, and colorectal cancer, enhanced mucosal and systemic immune responses, and improved the efficacy of tumor treatment and prevention, especially showing a significant anti-tumor protective immune response in the treatment and prevention of lung cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

A recombinant adenovirus vector tumor vaccine, a preparation method therefor, and use thereof. An antigen encoded by the recombinant adenovirus vector tumor vaccine comprises any one or a combination of two or more of antigenic peptide epitopes of a KRAS protein. The recombinant adenovirus vector tumor vaccine encodes multiple KRAS tumor-specific antigenic peptides, and exhibits a good killing effect on tumors driven by KRAS mutations, especially on lung tumors. The vaccine can be administered via nebulized inhalation, intramuscular injection followed by nebulized inhalation, nebulized inhalation followed by intramuscular injection, intramuscular injection, or simultaneous intramuscular injection and nebulized administration. After nebulization, the vaccine can reach the lungs via nasal or oral inhalation, generating anti-tumor protective immune responses in the respiratory tract and lungs and throughout the body, thereby enhancing the utilization rate and therapeutic efficacy of the vaccine.
Need to check novelty before this filing date? Find Prior Art